Hematology · Multiple MyelomaRegulatory Approvalregulatorymid-term

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:32:19 AM

Assessment confidence: 86% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental NDA for REVLIMID is a significant regulatory milestone that could enhance Bristol Myers Squibb's competitive position in the hematology space. This development necessitates close monitoring of the FDA review process and potential market shifts that may arise from label changes or new indications. Regulatory context from FDA (FDA AP — REVLIMID (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (23 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market shifts and strategize around the implications of this supplemental approval. The strongest clinical anchor is Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (bristol myers squibb). In Hematology · Multiple Myeloma, 8 regulatory and 7 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global (Bristol Myers Squibb) — entity match (bristol myers squibb). Secondary pressure from U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — REVLIMID (SUPPL) (FDA). Entity match (bristol myers squibb); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the supplemental NDA could lead to increased market share for REVLIMID, impacting revenue streams for both Bristol Myers Squibb and its competitors in the multiple myeloma market.
Bristol Myers Squibb document relevant to the signal.
Lead sponsor: Genentech, Inc.. The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Portfolio teams should prepare for potential market shifts and strategize around the implications of this supplemental approval.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review process and any subsequent announcements regarding label changes or indications.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ELIQUIS (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OPDUALAG (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OPDIVO (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OPDIVO QVANTIG (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source

Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
REVLIMID
competitors with similar therapies

Commercial impact

medium

If approved, the supplemental NDA could lead to increased market share for REVLIMID, impacting revenue streams for both Bristol Myers Squibb and its competitors in the multiple myeloma market.

Regulatory impact

medium

The acceptance of the supplemental NDA indicates a positive regulatory trajectory, but the final approval and any label changes will need to be closely monitored for compliance and market implications.

What to watch

Monitor the timeline for the FDA's review process and any subsequent announcements regarding label changes or indications.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.